Abstract-The purpose of this study was to investigate the role of dipeptidyl peptidase IV in regulating the effects of 2 of its substrates, neuropeptide Y 1-36 and peptide YY 1-36 , on proliferation of and collagen production by preglomerular vascular smooth muscle and glomerular mesangial cells from spontaneously hypertensive and normotensive rats. In cells from hypertensive rats, neuropeptide Y 1-36 and peptide YY 1-36 stimulated [ 
I
nhibitors of dipeptidyl peptidase IV (DPPIV), for example, sitagliptin, represent a novel class of antidiabetic drugs for treatment of type 2 diabetes mellitus that afford sustained reductions in hemoglobin A 1c with a low risk of hypoglycemia and little effect on body weight. 1 Because millions of patients will be taking DPPIV inhibitors for life, there is some urgency to more fully understand the long-term risks associated with DPPIV inhibition. The long-term risks of DPPIV inhibitors in the setting of hypertension are of particular interest, because frequently this condition is a comorbidity in type 2 diabetics. 2 DPPIV metabolizes incretin hormones, such as gastric inhibitory polypeptide and glucagon-like peptide-1 (GLP-1). 3 Consequently, DPPIV inhibitors raise circulating levels of incretin hormones and thereby exert antidiabetic actions by increasing insulin release. 3 However, there are Ն35 known peptide substrates for DPPIV, 4, 5 and, therefore, inhibition of DPPIV increases levels of an array of biologically active peptides. Long-term increases in some of these peptide substrates of DPPIV may entail risks. For example, Brown et al 6 provide evidence that DPPIV inhibitors increase angioedema risk in patients treated with angiotensin-converting enzyme inhibitors, most likely because of blockade of substance P metabolism. With respect to other substrates for DPPIV that may entail risks, 2 peptides of particular importance are neuropeptide Y (NPY) and peptide YY (PYY) . Both of these peptides are members of the pancreatic polypeptide-fold family, 7 and the kidney (a major target organ for diabetes mellitusinduced damage) is likely exposed to high levels of these endogenous peptides. For example, renal sympathetic nerves release NPY in response to central nervous systemmediated activation of renal sympathetic tone, 8 resulting in high local levels of NPY in sympathetically innervated renal microvessels. Also, NPY is made by renal epithelial cells and released into the renal interstitium, where it can affect vascular and glomerular cells. 9 With regard to PYY , fatty meals release this peptide into the systemic circulation from endocrine L-cells in the gastrointestinal tract producing physiologically active levels of PYY in plasma, 10, 11 and this circulating PYY would be delivered to the renal microcirculation and glomeruli via the blood stream. Type 2 diabetics, particularly those with the metabolic syndrome, have increased renal sympathetic tone 12 and often ingest fatty meals. 13 Thus, diabetics likely would have high renal levels of both NPY and PYY , and inhibition of DPPIV would increase these elevated levels.
Both NPY and PYY are potent endogenous agonists of Y 1 receptors. 7 However, DPPIV is anchored to the cell surface and efficiently converts PYY to PYY and NPY to NPY 3-36 by cleaving 2 amino acids from the N-termini of PYY and NPY . 3, 5 DPPIV could just as logically be named "NPY-converting enzyme," because the k cat /Michaelis constant of DPPIV for NPY is Ϸ36-fold and 73-fold greater for NPY compared with GLP-1 and gastric inhibitory polypeptide, respectively. 5 Whereas PYY 1-36 and NPY are potent Y 1 receptor agonists, PYY and NPY are inactive at Y 1 receptors but are selective Y 2 receptor agonists.
14 Thus, likely DPPIV inhibitors chronically increase Y 1 receptor activation in preglomerular microvascular smooth muscle (PGVSMCs) and glomerular mesangial cells (GMCs).
Because diabetic nephropathy entails hypercellarity of glomeruli and increased extracellular matrix production in glomeruli, a significant unanswered question is whether PYY and NPY 1-36 stimulate proliferation of and collagen production by PGVSMCs and GMCs and whether DPPIV modulates these responses. Accordingly, the goals of the present study were to determine in PGVSMCs and GMCs: (1) the expression of DPPIV mRNA, the expression of DPPIV protein, and DPPIV activity; (2) whether there is an interaction between PYY 1-36 and DPPIV and NPY and DPPIV such that the effects of PYY and NPY 1-36 on proliferation and collagen production are enhanced by inhibition of DPPIV in PGVMSCs and GMCs; and (3) whether the expression and function of DPPIV and actions of PYY and NPY 
Methods
Animals, isolation and culture of PGVSMCs and GMCs, quantitative real-time PCR for DPPIV, Western blotting for DPPIV, assay for PYY , extraction of sitagliptin, assessment of cell proliferation and collagen production, and statistical analysis are available in the online-only Data Supplement.
Results

Expression of DPPIV mRNA and Protein in PGVSMCs and GMCs
DPPIV mRNA was detected by quantitative real-time PCR in PGVSMCs and GMCs obtained from spontaneously hypertensive rats (SHRs) and normotensive Wistar-Kyoto rats (WKYs). DPPIV mRNA expression was similar in SHR PGVSMCs compared with WKY PGVSMCs and was similar in SHR GMCs compared with WKY GMCs; however, overall DPPIV mRNA levels were lower in GMCs compared with PGVSMCs ( Figure 1A ). Western blots for DPPIV revealed a single band at 55 kDa in both cell types for both strains using 2 different antibodies ( Figure 1B ). This 55-kDa band is consistent with the datasheet for the DPPIV antibody 10940-1-AP and with a report by Bauvois. 15 Bands were digitized and normalized to ␤-actin. DPPIV protein levels were similar in SHR versus WKY PGVSMCs and tended to be lower in SHR compared with WKY GMCs, although this did not achieve statistical significance ( Figure 1C ). Overall, DPPIV protein levels were lower in GMCs compared with PGVSMCs.
Conversion of PYY 1-36 to PYY 3-36 in SHR PGVSMCs and GMCs
Confluent monolayers of cells were incubated in PBS for 15 minutes with 0, 3, or 10 nmol/L of PYY 1-36 without or with sitagliptin, and the medium was assayed for PYY . In both PGVSMCs ( Figure 2A ) and GMCs ( Figure 2B ), incubation with 3 and 10 nmol/L of exogenous PYY 1-36 increased PYY 3-36 medium levels to Ϸ6-fold and 13-fold of basal, respectively. Sitagliptin significantly attenuated the increase in PYY 3-36 levels in PGVSMCs and GMCs; however, sitaglipin did not abolish the PYY 1-36 -induced increase in PYY 3-36 levels in either cell type. The sitagliptin-inhibitable PYY 3-36 production (PYY 3-36 levels in the absence of sitagliptin minus the average levels of PYY in the presence of sitagliptin) was greater in PGVSMCs compared with GMCs ( Figure 2C ).
Effects of NPY 1-36 , PYY 1-36 , and Sitagliptin on [ 3 H]-Thymidine Incorporation in SHR and WKY PGVSMCs
In SHR PGVSMCs, 2-factor ANOVA indicated a significant interaction between sitagliptin and NPY 1-36 ( Figure 3A ) and sitagliptin and PYY ( Figure 3C) Figure 3B ) and PYY ( Figure 3D ) significantly but very mildly increased [ 3 H]-thymidine incorporation, and these effects were not augmented by sitagliptin. 
Effects of NPY 1-36 , PYY 1-36 , and Sitagliptin on Cell Number in SHR and WKY PGVSMCs
In SHR PGVSMCs, 2-factor ANOVA indicated a significant interaction between sitagliptin and NPY 1-36 ( Figure 4A ) and sitagliptin and PYY (Figure 4C ) on cell number. NPY and PYY increased cell number, and sitagliptin enhanced the growth effects of NPY and PYY . In WKY PGVSMCs, NPY (Figure 4B ) and PYY (Figure 4D ) significantly but very mildly increased cell number; however, these responses were not augmented by sitagliptin.
Effects of NPY 1-36 , PYY 1-36 , and Sitagliptin on [ 3 H]-Proline Incorporation in SHR and WKY PGVSMCs
In SHR PGVSMCs, 2-factor ANOVA indicated a significant interaction between sitagliptin and NPY 1-36 on [ 3 H]-proline incorporation ( Figure 5A ). NPY Figure 5C) ; however, the interaction between sitagliptin and PYY was not statistically significant; there was a trend in this regard (Pϭ0.1138). In WKY PGVSMCs, NPY ( Figure 5B) and PYY (Figure 5D ) significantly but very mildly increased [ 3 H]-proline incorporation, and these effects were not augmented by sitagliptin.
Effects of NPY 1-36 , PYY 1-36 , and Sitagliptin on [ 3 H]-Thymidine Incorporation in SHR and WKY GMCs
In SHR GMCs, 2-factor ANOVA indicated a significant interaction between sitagliptin and NPY 1-36 and sitagliptin and PYY 1-36 on [ 3 H]-thymidine incorporation (Figure S1A and S1C, respectively, available in the online-only Data Supplement). NPY and PYY 1-36 stimulated [ 3 H]-thymidine incorporation, and this response was enhanced by sitagliptin. In WKY GMCs, NPY and PYY 1-36 significantly but very mildly increased [ 3 H]-thymidine incorporation, and these effects were not augmented by sitagliptin ( Figure S1B and S1D, respectively).
Effects of NPY 1-36 , PYY 1-36 , and Sitagliptin on Cell Number in SHR and WKY GMCs
In SHR GMCs, 2-factor ANOVA indicated a significant interaction between sitagliptin and NPY 1-36 and sitagliptin and PYY 1-36 on cell number ( Figure S2A and S2C, respectively). NPY and PYY 1-36 increased cell number, and sitagliptin enhanced the growth effects of NPY and PYY . In WKY PGVSMCs, NPY and PYY 1-36 significantly but very mildly increased cell number; however, these responses were not augmented by sitagliptin ( Figure S2B and S2D, respectively).
Effects of NPY 1-36 , PYY 1-36 , and Sitagliptin on [ 3 H]-Proline Incorporation in SHR and WKY GMCs
In SHR GMCs, 2-factor ANOVA indicated a significant interaction between sitagliptin and NPY 1-36 on [ 3 H]-proline incorporation ( Figure S3A ). NPY Figure S4A and S4B, respectively) either in the absence or presence of sitagliptin. In SHR GMCs, NPY and PYY 3-36 significantly but very mildly increased [ 3 H]-thymidine incorporation, and these effects were not augmented by sitagliptin ( Figure S4C and S4D (Figure 6 ). This complete inhibition by BIBP3226 was also observed for the combination effects of sitagliptin plus NPY and sitagliptin plus PYY .
Effects of GLP-1 on Cell Number in SHR and WKY PGVSMCs
Because GLP-1 is also an important substrate for DPPIV, GLP-1 induces vasodilation, 16, 17 and vasodilators often are associated with inhibition of vascular smooth muscle cell growth, we also examined the effects of GLP-1(7-36) on proliferation of SHR and WKY PGVSMCs in the absence and presence of sitagliptin. At concentrations from 1 to 100 nmol/L, GLP-1 had little if any effect on platelet-derived growth factor (PDGF)-induced proliferation of either SHR or WKY PGVSMCs, and there was no interaction between sitagliptin and GLP-1 in either SHR or WKY PGVSMCs ( Figure S5 ).
Discussion
The present results indicate that DPPIV message and protein are expressed in vascular and glomerular cellular elements and could, therefore, importantly influence the metabolism of NPY 1-36 and PYY . Because we do not have an assay that distinguishes NPY 1-36 from NPY 3-36 yet we do have an assay that detects PYY 3-36 without cross-reacting with PYY , in the present study we assessed the ability of DPPIV to metabolize pancreatic polypeptide-fold peptides by measuring the production of PYY 3-36 from PYY 1-36. Likely, both peptides are metabolized similarly by DPPIV, so the results for PYY 1-36 metabolism should reflect the ability of DPPIV to metabolize NPY . Indeed, our results show that the expression of DPPIV message and protein by PGVSMCs and GMCs is associated with the ability of these cell types to metabolize PYY to PYY . Importantly, sitagliptin, a potent and selective inhibitor of DPPIV, 1 suppresses the conversion of PYY to PYY in both cell types. This finding confirms that at least a portion of the enzymatic activity that converts PYY to PYY in PGVSMCs and GMCs is attributed to DPPIV. We hypothesize that inhibition of DPPIV may have adverse renal consequences because proliferation of PGVSMCs and GMCs mediates detrimental changes in renal structure and function 18 ; activation of Y 1 receptors may stimulate growth of aortic vascular smooth muscle cells, 19 so it is conceivable that Y 1 receptors could stimulate growth of PGVSMCs and GMCs; NPY and PYY but not NPY and PYY 3-36 activate Y 1 receptors; DPPIV is present in PGVSMCs and GMCs; and inhibition of DPPIV reduces the metabolism of pancreatic polypeptide-fold peptides in PGVSMCs and GMCs.
Importantly, the results of the present study demonstrate that NPY and PYY 1-36 stimulate proliferation of PGVSMCs and GMCs. Although these effects of NPY and PYY are barely perceptible in PGVSMCs and GMCs obtained from normotensive rats, the ability of NPY and PYY to stimulate proliferation of PGVSMCs and GMCs is pronounced in cells from genetically hypertensive animals. These findings underscore the potential for NPY and PYY to regulate cell growth in renovascular and glomerular cellular elements in genetically susceptible animals.
Real-time PCR and Western blotting show similar DPPIV mRNA and protein levels in PGVSMCs and GMCs from SHRs versus WKYs, yet NPY 1-36 and PYY have little effect on proliferation of WKY PGVSMCs and GMCs. Our previously published work demonstrates that Y 1 and Y 2 receptor expression is not different in freshly isolated preglomerular microvessels from SHRs versus WKYs. 20 However, our previously published work does show that signaling via G i -linked receptors is enhanced in the renal vasculature of SHRs versus WKYs. 20 Inasmuch as Y 1 receptors are G icoupled receptors, the most likely reason that NPY and PYY stimulate growth more in SHR versus WKY PGVSMCs and GMCs is that postreceptor signaling via the G i pathway is enhanced in SHR PGVSMCs and GMCs.
The present study also demonstrates that the progrowth effects of NPY and PYY in cells from genetically susceptible rats are enhanced by inhibition of DPPIV, whereas inhibition of DPPIV seems to have little effect on the progrowth effects of NPY and PYY in cells from genetically nonsusceptible rats. The enhancement of the progrowth effects of NPY and PYY in cells from genetically susceptible animals by inhibition of DPPIV is likely mediated by reducing the rate of metabolism of NPY and PYY to NPY and PYY , respectively, leading to greater activation of Y 1 receptors. The evidence for this conclusion is that, unlike NPY 1-36 and PYY , NPY and PYY have little effect on cell growth even in cells from genetically susceptible animals, and the progrowth effects of both NPY and PYY are abolished by the selective Y 1 receptor antagonist BIBP3226.
In addition to accelerating cell proliferation, our experiments support the conclusion that both NPY and PYY stimulate collagen production by both PGVSMCs and GMCs, with the effect being more pronounced in cells from genetically hypertensive animals. The ability of NPY 1-36 to stimu- 
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Hypertension September 2012 late extracellular matrix production was significantly enhanced by DPPIV inhibition in SHR PGVSMCs and SHR and WKY GMCs. Although the interaction between sitagliptin and PYY did not reach statistical significance, there was a strong trend toward such an interaction in SHR PGVSMCs and GMCs. Although the focus of the present study was NPY 1-36 and PYY , these peptides are not the only substrates for DPPIV that could enhance proliferation of PGVSMCs and GMCs. An important question, therefore, is whether the effects of sitagliptin observed in the present study can be attributed entirely to an interaction with the metabolism of NPY and PYY . Importantly, in our experiments we used PDGF as our growth stimulant (ie, we did not add serum). So the only progrowth factors present in the medium were PDGF and NPY or PYY . Because PDGF is not a substrate for DPPIV, we are reasonably certain that the effects of sitagliptin were mediated in our experimental paradigm via inhibition of NPY and PYY metabolism. This hypothesis is further supported by the complete blockade of the effect of sitagliptin by antagonism of Y 1 receptors.
Nonetheless, in vivo sitagliptin certainly affects the metabolism of multiple peptides, and any adverse effects of sitagliptin on renal morphology in vivo could very well be because of enhancement of the levels of multiple progrowth peptides. To address this issue, it will be necessary to examine in vitro the interaction of sitagliptin with all of the possible growth-promoting peptides that are metabolized by DPPIV. The lack of an interaction between GLP-1 and sitagliptin on PDGF-induced proliferation of either SHR PGVSMCs or GMCs suggests that in vivo the progrowth effects of DPPIV inhibitors mediated by increases in NPY and PYY are unlikely to be offset by increases in GLP-1. However, in vivo DPPIV inhibitors decrease glucagon secretion somewhat, 21 and glucagon may stimulate GMC proliferation. 22 Thus, it is conceivable that in vivo decreases in glucagon-driven promotion of GMC growth could offset some of the progrowth effects attributed to enhanced Y 1 receptor activation.
Perspectives
In 2006, the US Food and Drug Administration approved sitagliptin, the first DPPIV inhibitor to attain US Food and Drug Administration approval for the treatment of type 2 diabetes mellitus. More recently, other DPPIV inhibitors have been approved by the US Food and Drug Administration, including saxagliptin and linagliptin, and many other DPPIV inhibitors are in development. In all likelihood, DPPIV inhibitors will become widely used to treat type 2 diabetics, many of whom will have hypertension, vascular disease, and renal diseases as comorbidities. A recent study by Kirino et al 23 shows that, in DPPIV-deficient rats, streptozotocininduced diabetes mellitus profoundly and chronically reduces creatinine clearance when compared with DPPIV-expressing rats. Moreover, case reports are now appearing linking DPPIV inhibitors to renal impairment in patients with type 2 diabetes mellitus. 24 The present study demonstrates that cellular elements in the preglomerular renal microcirculation and glomeruli express DPPIV message, protein, and activity. Also, our results indicate that, in cells from genetically susceptible animals, proliferation of and extracellular matrix production by PGVSMCs and GMCs can be driven by NPY and PYY and that DPPIV inhibition enhances these effects of NPY and PYY . Because in vivo kidneys are normally exposed to high levels of NPY and PYY , long-term treatment with DPPIV inhibitors could enhance proliferation of and collagen production by PGVSMCs and GMCs in genetically susceptible hypertensive patients. Long-term treatment with DPPIV inhibitors might, therefore, entail a risk of renal dysfunction attributed to abnormal proliferation of cells in the preglomerular microcirculation and glomeruli. Therefore, the present findings suggest vigilance as DPPIV inhibitors become widely used in the treatment of type 2 diabetics with hypertension, vascular disease, or renal dysfunction. The recent finding that DPPIV inhibition may alter the antihypertensive effects of angiotensin-converting enzyme inhibitors 25 further underscores this concern.
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